A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patientsMatthew S. Davids, Jennifer R. Brown, John Hanna et al.|Leukemia|2020Cited by 36
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Jennifer R. Brown, Alec Griffith et al.|Leukemia|2021Cited by 20